NBT-NM108

DRUG4 trials

Sponsors

Notitia Biotechnologies Company, Suhayl Dhib-Jalbut, MD, Howard S. Hochster, MD, Rutgers, The State University of New Jersey

Conditions

Metastatic Colon CarcinomaMultiple SclerosisObesityPrader-Willi SyndromeStage IV Colon Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVC Colon Cancer AJCC v8

Phase 1

HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)

CompletedNCT04574024

Suhayl Dhib-Jalbut, MDMultiple Sclerosis

Start: 2022-03-21End: 2024-07-15Updated: 2024-12-17

Phase 2

NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

CompletedNCT04540406

Notitia Biotechnologies CompanySuspected or Confirmed COVID-19

Start: 2021-11-02End: 2022-03-14Updated: 2024-10-08

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

RecruitingNCT05296681

Howard S. Hochster, MDMetastatic Colon Carcinoma, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8 +2

Start: 2022-05-03End: 2027-06-01Target: 42Updated: 2026-01-06

Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome

CompletedNCT05541003

Rutgers, The State University of New JerseyObesity, Prader-Willi Syndrome

Start: 2023-01-06End: 2023-05-30Updated: 2024-07-16